Insomnia

In patients with post COVID-19 related fatigue, the mean insomnia severity was 11.46 and prevalence of clinical insomnia was 64%.

Drs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.

Nathaniel F. Watson, MD, leads a discussion on gaps in care and unmet needs for patients and healthcare professionals in the area of sleep disorders.

Experts in sleep medicine share emerging treatments in the pipeline for the management of sleep disorders.

Investigators are urging for more research on the mechanisms involved with comorbid insomnia and obstructive sleep apnea (OSA) to reduce the mortality risk in patients with both sleep disorders.

Drs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson examine setting treatment expectations with patients and treatment adherence for sleep disorders.

Ashgan A. Elshinawy, DO, shares her approach to treatment selection of DORAs and switching therapies for the management of sleep disorders.

Nathaniel F. Watson, MD, highlights the use of daridorexant for treating patients with insomnia as seen from phase 3 trials and data presented at the World Sleep 2022 meeting and managing adverse events.

Drs Ashgan A. Elshinawy, C. Michael Gibson, and Nathaniel F. Watson discuss FDA-approved medications currently used for the treatment of sleep disorders and insomnia, and comment on the difference between DORAs.

Nathaniel F. Watson, MD, reviews the pathways involved in sleep and wakefulness cycles as it relates to sleep disorders.

Dr Ashgan A. Elshinawy and C. Michael Gibson considers safety and efficacy factors when approaching treatment selection for sleep disorders and insomnia.

A study featured at CHEST 2022 investigated INCS in children with OSAS to determine if the therapy improved their symptoms, polysomnography findings, behavior, and quality of life.

New analyses suggest insomnia symptoms among older patients may play a pivotal role in the relationship between objective and self-reported cognition.

Ashgan A. Elshinawy, DO, comments on engaging patients in conversations around managing sleep disorders with co-occurring health conditions.

Experts in sleep medicine stress the importance of early diagnosis of sleep disorders and how they approach treatment in their clinics.

Dr Nathaniel F. Watson reviews screening patients for sleep disorders and referral to sleep specialists.

Nathaniel F. Watson, MD; Ashgan A. Elshinawy, DO; and C. Michael Gibson, MD, examine complications patients encounter with sleep disorders, including for insomnia, and the impact on their quality of life.

Women who were socially isolated were more likely to have insomnia than women who were socially integrated.

A cross-sectional analysis from the France COVID-19 lockdown period resulted in a predictive model for insomnia risk.

Ashgan A. Elshinawy, DO, leads a discussion on the co-occurrence and relationship between sleep disorders and different health conditions in patients.

Dr Nathaniel F. Watson, MD, provides insight on the prevalence of various sleep disorders, including insomnia, and patient populations at high-risk for developing these disorders.

A comprehensive literature review supports the association between sleep disorders and chronic migraine, leading to poor quality of life, loss of workforce and economic burden.

A new analysis suggests raise levels of zinc, iron, lead and aluminum—linked to cigarette use—is positively correlated with insomnia.

Breaking phase 3 data were just announced from the results of the daridorexant (Quviviq) clinical trial for adults with insomnia in Japan.

A profound escalation in the frequency of nightmares, independently associated with suicide risk, occurred alongside related sleep and mental health outcomes during the COVID-19 pandemic.

The research examined how anxiety and pre-bedtime behaviors that are often reported in primary care settings impact sleep health and discussed targeted interventions for effective treatment.

The study explores the relationship between the ascending arousal network, its alterations, and its connections with cortical networks in chronic insomnia disorder.

A majority of individuals who received one of the various cannabinoid products experienced a significant improvement in sleep quality and duration.

"Collectively, this work highlights and supports chronotype as a potential risk factor related to type 2 diabetes and cardiovascular disease risk," investigators wrote.

Various consequences have been linked to nightmares and can have a severe impact on mental health, even leading to increased risk of suicide.